BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 36 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVES: Proteinuric diabetic kidney disease frequently progresses to ESRD. Control of BP delays progression, but the optimal BP to improve outcomes remains unclear. The objective of this analysis was to evaluate the relationship between BP and renal outcomes in proteinuric diabetic kidney disease. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: BP data from all 1448 randomized participants in the Veterans Affairs Nephropathy in Diabetes Trial were included in a post hoc analysis. The associations of mean on-treatment BP with the primary end point (decline in eGFR, ESRD, or death), renal end point (decline in eGFR or ESRD), rate of eGFR decline, and mortality were measured. RESULTS: The median (25th, 75th percentile) follow-up time was 2.2 (1.2, 3.0) years. There were 284 primary end points. In univariate analyses, both mean systolic and mean diastolic BPs were strongly associated (P<0.001) with the primary end point. After multivariate adjustment, the hazard of developing the primary end point became progressively higher as mean systolic BP rose from <120 to ≥ 150 mmHg (P=0.02), with a significantly higher hazard ratio for 140-149 versus 120-129 mmHg (1.51 [1.06, 2.15]; P=0.02). There was also a significant association of mean diastolic BP with the hazard of developing the primary end point (P<0.01), with a significantly higher hazard ratio when mean diastolic BP was 80-89 versus 70-79 mmHg (1.54 [1.05, 2.25]; P=0.03); there was also a strong trend when mean diastolic BP was <60 mmHg. Associations between BP and both renal end point and rate of eGFR decline were similar to those with the primary end point. No association of BP with mortality was observed, possibly because of the limited number of mortality events. CONCLUSIONS: In patients with proteinuric diabetic kidney disease, mean systolic BP ≥ 140 mmHg and mean diastolic BP ≥ 80 mmHg were associated with worse renal outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypertension is a strong risk factor for the development and progression of CKD (66).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypertension is a strong risk factor for the development and progression of CKD (67).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [67]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Once diagnosed with hypertension, an individual is 2.5 times more likely to be diagnosed with T2D within the next 5 years.181,182”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [181]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Hypertension is not only more prevalent in persons with T2D than in the general population, but hypertension also predicts progression to T2D.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [181]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Klahr, S., Levey, A. S., Beck, G. J., Caggiula, A. W., Hunsicker, L., Kusek, J. W., & Striker, G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403313301301 · Cited by 2,328
The J-Curve Phenomenon in Hypertension
Kang, Y.-Y., & Wang, J.-G. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,530
Preserving renal function in adults with hypertension and diabetes: A consensus approach
Bakris, G. L., Williams, M., Dworkin, L., Elliott, W. J., Epstein, M., Toto, R., Tuttle, K., Douglas, J., Hsueh, W., & Sowers, J. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.16225 · Cited by 1,411
(2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.03.003 · Cited by 1,245
Combined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169
Self-citationAgodoa, L. Y. (2001) · JAMA · doi:10.1001/jama.285.21.2719 · Cited by 944
Parving, H.-H., Smidt, U., Andersen, A., & Svendsen, P. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92462-5 · Cited by 867
Blood Pressure Lowering in Type 2 Diabetes: A Systematic Review and Meta-analysis
Emdin, C. A., Rahimi, K., Neal, B., Callender, T., Perkovic, V., & Patel, A. (2015) · JAMA · doi:10.1001/jama.2014.18574 · Cited by 854 · cited 1×
“Similarly, recent large analyses in predominantly nonproteinuric type II diabetes support a goal SBP of ,140 mmHg (29,30).”
ResultSchrier, R. W., Estacio, R. O., Esler, A., & Mehler, P. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00213.x · Cited by 851 · cited 1×
“In the normotensive Appropriate Blood Pressure Control in Diabetes Trial, intensive BP control (128/75 mmHg) versus moderate BP control (137/81 mmHg) did not affect rate of renal function decline (27).”
BackgroundLong-term antihypertensive treatment inhibiting progression of diabetic nephropathy
Mogensen, C. E. (1982) · BMJ · doi:10.1136/bmj.285.6343.685 · Cited by 760
(2000) · PubMed · Cited by 691
Ruggenenti, P., Perna, A., Loriga, G., Ganeva, M., Ene-Iordache, B., Turturro, M., Lesti, M., Perticucci, E., Chakarski, I. N., Leonardis, D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71082-5 · Cited by 644
Keane, W. F., Brenner, B. M., de Zeeuw, D., Grunfeld, J.-P., McGill, J., Mitch, W. E., Ribeiro, A. B., Shahinfar, S., Simpson, R. L., Snapinn, S. M., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00885.x · Cited by 539
Effect of antihypertensive treatment on kidney function in diabetic nephropathy.
Parving, H. H., Andersen, A. R., Smidt, U. M., Hommel, E., Mathiesen, E. R., & Svendsen, P. A. (1987) · BMJ · doi:10.1136/bmj.294.6585.1443 · Cited by 537
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.46 · Cited by 521
(2004) · PubMed · Cited by 502
Bakris, G. L. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.13.1555 · Cited by 469
Bjorck, S., Nyberg, G., Mulec, H., Granerus, G., Herlitz, H., & Aurell, M. (1986) · BMJ · doi:10.1136/bmj.293.6545.471 · Cited by 405
Pohl, M. A., Blumenthal, S., Cordonnier, D. J., De Alvaro, F., DeFerrari, G., Eisner, G., Esmatjes, E., Gilbert, R. E., Hunsicker, L. G., de Faria, J. B. L., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004110919 · Cited by 375 · cited 2×
“(14) analyzed the association of mean achieved BP with outcomes, which was also done in our study.”
MethodResultParving, H. H., Hommel, E., & Smidt, U. M. (1988) · BMJ · doi:10.1136/bmj.297.6656.1086 · Cited by 328
Taler, S. J., Agarwal, R., Bakris, G. L., Flynn, J. T., Nilsson, P. M., Rahman, M., Sanders, P. W., Textor, S. C., Weir, M. R., & Townsend, R. R. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.03.018 · Cited by 198 · cited 1×
“What are the current guidelines in patients with proteinuric DKD? The 2012 Kidney Disease Improving Global Outcomes guidelines recommend a goal BP of ,130/80 mmHg (31,32).”
BackgroundEffect of intensive blood pressure control on the course of type 1 diabetic nephropathy
Lewis, J. B., Berl, T., Bain, R. P., Rohde, R. D., & Lewis, E. J. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70036-3 · Cited by 181
Peralta, C. A., Norris, K. C., Li, S., Chang, T. I., Tamura, M. K., Jolly, S. E., Bakris, G., McCullough, P. A., Shlipak, M., & KEEP Investigators, F. T. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.619 · Cited by 132
The importance of blood pressure control in the patient with diabetes
Bakris, G. L. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.10.018 · Cited by 114 · cited 1×
“BP control is important in preventing adverse cardiovascular and kidney outcomes in patients with diabetes and hypertension (2).”
BackgroundLeehey, D. J., Kramer, H., Daoud, T. M., Chatha, M. P., & Isreb, M. A. (2005) · BMC Nephrology · doi:10.1186/1471-2369-6-8 · Cited by 58
Self-citationAmbulatory Blood Pressure Variability Is Increased in Diabetic Hypertensives
Ozawa, M., Tamura, K., Iwatsubo, K., Matsushita, K., Sakai, M., Tsurumi‐Ikeya, Y., Azuma, K., Shigenaga, A.-I., Okano, Y., Masuda, S., et al. (2008) · Clinical and Experimental Hypertension · doi:10.1080/10641960802068477 · Cited by 48
Trocha, A. K., Schmidtke, C., Didjurgeit, U., Mühlhauser, I., Bender, R., Berger, M., & Sawicki, P. T. (1999) · Journal of Hypertension · doi:10.1097/00004872-199917100-00019 · Cited by 44
Effects of intensification of antihypertensive care in diabetic nephropathy
Sawicki, P. T., Mühlhauser, I., Didjurgeit, U., & Berger, M. (1995) · Journal of Diabetes and its Complications · doi:10.1016/1056-8727(95)80030-i · Cited by 7
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Thomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P., Groop, P.-H., & Cooper, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.18 · Cited by 1,230
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
LeRoith, D., Biessels, G. J., Braithwaite, S. S., Casanueva, F. F., Draznin, B., Halter, J. B., Hirsch, I. B., McDonnell, M. E., Molitch, M. E., Murad, M. H., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00198 · Cited by 568
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s011 · Cited by 460
“Hypertension is a strong risk factor for the development and progression of CKD (78).”
Background
Metadata
- Authors
- Leehey, D. J., Zhang, J. H., Emanuele, N. V., Whaley-Connell, A., Palevsky, P. M., Reilly, R. F., Guarino, P., & Fried, L. F.
- Affiliations
- Loyola University Medical Center (US)
- VA Connecticut Healthcare System (US)
- University of Pittsburgh (US)
- VA North Texas Health Care System (US)
- Corresponding author
- Leehey, David J.
- Emanuele, Nicholas V.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2015-12
- Volume
- 10
- Issue
- 12
- Pages
- 2159-2169
- ISSN
- 1555-9041 (ISSN-L)
- PMC
- PMC4670761
- OpenAlex
- W1880991675
- Semantic Scholar
- 4ada66d1848bcba4f438c95df9007e6e5d850587
- Cited by
- 62
- References
- 37
- Citations by year
- 2025: 8 · 2024: 5 · 2023: 6 · 2022: 4 · 2021: 6 · 2020: 8 · 2019: 7 · 2018: 7 · 2017: 5 · 2016: 5 · 2015: 1
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Office of Research and Development
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- blood pressure, diabetic nephropathy, proteinuria, end-stage renal disease, estimated glomerular filtration rate decline, systolic blood pressure, diastolic blood pressure, renal outcomes, mortality, veterans
- MeSH terms
- Aged, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Blood Pressure, Diabetic Nephropathies, Double-Blind Method, Drug Therapy, Combination, Female, Glomerular Filtration Rate, Humans, Hypertension, Kidney Failure, Chronic, Male, Middle Aged, Proteinuria, Risk Factors, Time Factors, United States, United States Department of Veterans Affairs, Multivariate Analysis, Proportional Hazards Models, Treatment Outcome, Lisinopril, Disease Progression, Losartan, Angiotensin II Type 1 Receptor Blockers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.